Literature DB >> 26026586

High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.

Maria Devetzoglou1, Rodanthi Vyzoukaki2, Maria Kokonozaki2, Athina Xekalou3, Constantina A Pappa4, Anastasia Papadopoulou2, Athanasios Alegakis5, Nikolaos Androulakis2, Michael G Alexandrakis6,7.   

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm characterized by bone marrow infiltration from malignant plasma cells. Mast cells play an important role in inflammation and angiogenesis in malignant diseases. The aim of the study was to evaluate the mast cell density in bone marrow of untreated MM patients with markers of disease activity such as serum interleukin-6 (IL-6), B2M, and C-reactive protein (CRP), the grade of bone marrow infiltration, and the levels of produced paraprotein. We studied 86 newly diagnosed MM patients (46 males, 40 females, mean age 59 ± 13.7 years). Thirty of them reached plateau phase after chemotherapy and 20 healthy volunteers. According to the criteria of International Staging System (ISS) staging system, 23 patients had stage I, 30 had stage II, and 33 had stage III. The serum concentrations of CRP, B2M, and IL-6, and the mast cell density (MCD) values were significantly higher in MM patients' group (1.6 ± 1.8, 4.3 ± 2.9, 7.1 ± 5.1, and 9 ± 4.8), in comparison with those found in control group (0.4 ± 0.1, 1.5 ± 0.6, 1.1 ± 0.5, and 1.9 ± 0.7; p < 0.001 in all the cases). Significant differences were found between the grade of infiltration in bone marrow, and the paraprotein values in patients' serum before and after chemotherapy. Furthermore, there was a significant correlation between the MCD values and the prognostic markers CRP (r = 0.452, p < 0.0001), IL-6 (r = 0.475, p < 0.0001), bone marrow infiltration (r = 0.333, p < 0.0002), and serum paraprotein levels(r = 0.221, p < 0.04). High MCD values strengthen the hypothesis that mast cells participate in the pathogenesis of disease progression and may be used as an indicator of the disease activity.

Entities:  

Keywords:  Acute phase proteins; Angiogenesis; Mast cells; Multiple myeloma; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26026586     DOI: 10.1007/s13277-015-3586-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

Review 1.  Multiple myeloma.

Authors:  J Bladé; M Teresa Cibeira; C Fernández de Larrea; L Rosiñol
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

2.  Short or long survival in multiple myeloma. A simple method for determining the prognosis.

Authors:  Judit Várkonyi; Edina Bajzik; Adám Fazakas; Sándor Sipka; István Karádi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

3.  Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.

Authors:  B G Durie; D Stock-Novack; S E Salmon; P Finley; J Beckord; J Crowley; C A Coltman
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

4.  The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix.

Authors:  L Benítez-Bribiesca; A Wong; D Utrera; E Castellanos
Journal:  J Histochem Cytochem       Date:  2001-08       Impact factor: 2.479

5.  Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein.

Authors:  D Kyriakou; H Papadaki; A G Eliopoulos; A Foudoulakis; M Alexandrakis; G D Eliopoulos
Journal:  Int J Hematol       Date:  1997-10       Impact factor: 2.490

6.  Effect of mast cells on tumor angiogenesis in lung cancer.

Authors:  M Tomita; Y Matsuzaki; T Onitsuka
Journal:  Ann Thorac Surg       Date:  2000-06       Impact factor: 4.330

7.  Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.

Authors:  Jatin Shah; Joan Bladé; Pieter Sonneveld; Jean-Luc Harousseau; Keith Lantz; Anil Londhe; Colin Lowery; Robert Z Orlowski
Journal:  Cancer       Date:  2011-02-15       Impact factor: 6.860

8.  The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.

Authors:  George Tsirakis; Constantina A Pappa; Maria Kaparou; Anna Boula; Vaitsa Katsomitrou; Athina Xekalou; Stavroula Kyriakaki; Michael G Alexandrakis
Journal:  Tumour Biol       Date:  2012-12-16

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression.

Authors:  Devandir Antonio de Souza; Vanina Danuza Toso; Maria Rita de Cássia Campos; Vanessa Soares Lara; Constance Oliver; Maria Célia Jamur
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more
  1 in total

1.  Mast cell density and its clinical relevance in Waldenström's macroglobulinemia.

Authors:  Richard Lemal; Stéphanie Poulain; Albane Ledoux-Pilon; Lauren Veronese; Andrei Tchirkov; Benjamin Lebecque; Thomas Tassin; Jacques-Olivier Bay; Frédéric Charlotte; Florence Nguyen-Khac; Marc Berger; Catherine Godfraind; Loïc Ysebaert; Frédéric Davi; Bruno Pereira; Véronique Leblond; Olivier Hermine; Romain Guièze; Franck Pagès; Olivier Tournilhac
Journal:  EJHaem       Date:  2022-02-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.